Relation among vascular endothelial growth factor, adhesion molecule protein CD44 v6 and short-term outcome of chemoradiotherapy in patients with non-small-cell lung cancer
Gao Shile
Hu Zongtao
Abstract：Objective To analyze the relation among vascular endothelial growth factor (VEGF),adhesion molecule protein CD44v6 and short-term outcome of chemoradiotherapy in patients with non-small-cell lung cancer(NSCLC).Methods Clinical data of 72 patients diagnosed of NSCLC from January 2013 to January 2015in the 105th Hospital of Chinese People's Liberation Army were retrospectively analyzed.All patients were treated with concurrent chemoradiotherapy for 1 month.Serum levels of VEGF and CD44 v6 were measured by enzyme linked immunosorbent assay 1 week before and 1 month after therapy.Relations of VEGF and CD44v6 with the 1-month efficacy of chemoradiotherapy were analyzed.Results Before and after therapy,serum levels of VEGF and CD44v6 in patients with smoking history were significantly higher than those in patients without smoking history;serum levels of VEGF and CD44v6 in squamous carcinoma patients were significantly higher than those in adenocarcinoma patients;serum levels of VEGF and CD44 v6 in patients with stage Ⅲ a + Ⅲ b cancer were significantly higher than those in patients with stage Ⅱ cancer(P ＜0.05 or P ＜0.01).Among 72 patients,there were 12 cases of complete remission,42 cases of partial remission,14 cases of stable disease and 4 cases of progressive disease;the objective response rate was 75.0％ (54/72);the disease control rate was 94.4％ (68/72).Serum levels of VEGF and CD44v6 after therapy were significantly lower than those before therapy[(565 ± 84)ng/L vs (595 ±102)ng/L,(431 ± 16)μg/L vs (461 ±21)μg/L] (P ＜0.05).In patients with complete remission,partial remission,objective response and disease control,serum levels of VEGF and CD44v6 significantly decreased after therapy (P ＜ 0.05 or P ＜ 0.01).In patients with stable disease,serum level of VEGF significantly decreased afte therapy (P ＜ 0.05).Conclusion Changes of serum VEGF and CD44 v6 may reflect clinical and pathological features of NSCLC;they can be used as predictive indicators for short-term efficacy and prognosis of chemoradiotherapy for NSCLC.
Keywords：Carcinoma,non-small-cell lungVascular endothelial growth factorsCD44 v6Concurrent chemoradiotherapy
Publication Date：2017-10-30
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：4( 1507-1510 )